IDEXX Laboratories, Inc.
NASDAQ:IDXXMedical - Diagnostics & Research
+$12.33 today
- Market cap
- $55.03B
- Beta
- 1.54
- P/E (TTM)
- 40.8
- EPS (TTM)
- $13.67
Volume 0.37M
Average 0.58M
IDXX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
IDEXX Laboratories, Inc.NASDAQ: IDXX
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows, but more slowly than its trailing trend
Q3 FY2026 revenue of $1.21B rose 9.9% year over year, behind the +11.9% change in trailing-twelve-month revenue. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 11 analysts of $4.75B (+10.3%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.21B-0.2% QoQ
- Last fiscal yearDec 2025
- $4.3B+10.4% YoY
- LTMSep 2026
- $4.66B+11.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.9% | +8.5% | -1.4 pp |
| 1 year | +10.4% | +10.3% | -0.1 pp |
| 3-year CAGR | +8.5% | +9.5% | +1.0 pp |
| 5-year CAGR | +9.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 4.3B USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +7.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.3B | +10.4% |
| FY2024 | 2024-12-31 | 3.9B | +6.5% |
| FY2023 | 2023-12-31 | 3.66B | +8.7% |
| FY2022 | 2022-12-31 | 3.37B | +4.7% |
| FY2021 | 2021-12-31 | 3.22B | — |
Revenue vs competitors
How IDXX compares with its peers on the latest reported figures
- IDXX's LTM Sep 2026 revenue of $4.66B is the 4th highest of the 5 companies compared; the peer median is $7.33B.
- Its year-over-year change of +11.9% is the 2nd highest of 5, against a peer median of +2.8%.
- Over three fiscal years its annual growth of +8.5% compares with a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $66.4B | +4.2% | +3.1% | |
| LTM Jun 2026 | $9.52B | +1.4% | +5.4% | |
| LTM Sep 2026 | $5.15B | +12.1% | +2.2% | |
| LTM Sep 2026 | $4.66B | +11.9% | +8.5% | |
| LTM Aug 2026 | $883.99M | -0.3% | +1.9% | |
| Peer median (excluding IDXX) | $7.33B | +2.8% | +2.7% | |
Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.22B | 3.37B | 3.66B | 3.9B | 4.3B |
| Cost of Revenue | 1.33B | 1.36B | 1.47B | 1.52B | 1.64B |
| Gross Profit | 1.89B | 2B | 2.19B | 2.38B | 2.66B |
| Gross Margin | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% |
| Research & Development | 161.01M | 254.82M | 190.95M | 219.79M | 251.21M |
| Selling, General & Admin | 796.4M | 850.75M | 901.89M | 1.03B | 1.05B |
| Operating Expenses | 957.4M | 1.11B | 1.09B | 1.25B | 1.3B |
| Depreciation & Amortization | 104.6M | 111.9M | 114.91M | 129.94M | 145.18M |
| EBITDA | 1.04B | 1.01B | 1.22B | 1.28B | 1.51B |
| EBITDA Margin | 32.3% | 30.1% | 33.3% | 32.7% | 35.0% |
| Operating Income | 932.03M | 898.77M | 1.1B | 1.13B | 1.36B |
| Operating Margin | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% |
| Interest Income | 434K | 1.07M | 5.63M | 12.7M | 2.42M |
| Interest Expense | 29.81M | 39.86M | 41.58M | 31.21M | 38.27M |
| Other Income / Expenses | (29.37M) | (38.79M) | (35.95M) | (18.51M) | (35.84M) |
| Income Before Tax | 902.65M | 859.97M | 1.06B | 1.11B | 1.32B |
| Pre-Tax Margin | 28.1% | 25.5% | 29.0% | 28.5% | 30.8% |
| Income Tax Expense | 157.81M | 180.88M | 216.13M | 221.96M | 264.73M |
| Net Income | 744.85M | 679.09M | 845.04M | 887.87M | 1.06B |
| Net Margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
| EPS (Basic) | 8.74 | 8.12 | 10.17 | 10.77 | 13.17 |
| EPS (Diluted) | 8.60 | 8.03 | 10.06 | 10.67 | 13.08 |
| Weighted Avg Shares | 85.2M | 83.62M | 83.07M | 82.47M | 80.1M |
| Weighted Avg Shares (Diluted) | 86.57M | 84.6M | 83.98M | 83.25M | 80.68M |
IDEXX Laboratories, Inc.
NASDAQ:IDXX
Intrinsic Alpha fair value
Locked
Current Price
$698.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.